Skip to main content

MINI REVIEW article

Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1434495

EGFRVIII and EGFR Targeted Chimeric Antigen Receptor T Cell Therapy in Glioblastoma

Provisionally accepted
Robert C. Sterner Robert C. Sterner 1Rosalie M. Sterner Rosalie M. Sterner 2*
  • 1 Inova Fairfax Hospital, Falls Church, Virginia, United States
  • 2 Mayo Clinic, Rochester, United States

The final, formatted version of the article will be published soon.

    Glioblastoma is the most common primary brain tumor. Although there have been significant advances in surgical techniques, chemo and immunotherapies, and radiation therapy, outcomes continue to be devastating for these patients with minimal improvements in survival. Chimeric antigen receptor T cell therapy is a revolutionary approach that is a new pillar in the treatment of cancer. CAR T cell therapy has produced remarkable results in hematological malignancies; however, multiple limitations currently prevent it from being a first-line therapy, especially for solid tumors. Epidermal growth factor receptor is classically amplified in glioblastoma, and a variant, EGFR variant III, is expressed on glioblastoma making it an exciting potential target for CAR T cell therapy. Although preclinical has exciting potential, clinical data has been heterogeneous. In this review, we assess the state of field of EGFR-targeted CAR T cells.

    Keywords: epidermal growth factor receptor, EGFR, Epidermal growth factor receptor variant III, EGFRvIII, Chimeric antigen receptor T cell, CAR T cell, Glioblastoma, Solid tumor

    Received: 17 May 2024; Accepted: 03 Sep 2024.

    Copyright: © 2024 Sterner and Sterner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Rosalie M. Sterner, Mayo Clinic, Rochester, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.